TSS
MCID: TXC005
MIFTS: 62

Toxic Shock Syndrome (TSS)

Categories: Infectious diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Toxic Shock Syndrome

Summaries for Toxic Shock Syndrome

Disease Ontology: 11 A commensal bacterial infectious disease that results in infection, has material basis in Streptococcus pyogenes or has material basis in Staphylococcus aureus , which produce toxins that are absorbed systemically and produce the systemic manifestations. The infection has symptom fever, has symptom rash, has symptom hypotension, has symptom multiorgan failure, has symptom desquamation, has symptom vomiting, has symptom diarrhea, has symptom headache, and has symptom nonfocal neurologic abnormalities.

MalaCards based summary: Toxic Shock Syndrome, also known as septic shock, is related to critical covid-19 and melioidosis, and has symptoms including hypotension, vomiting and fever. An important gene associated with Toxic Shock Syndrome is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Methylene blue and Dobutamine have been mentioned in the context of this disorder. Affiliated tissues include kidney, skin and skeletal muscle, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

Wikipedia: 75 Toxic shock syndrome (TSS) is a condition caused by bacterial toxins. Symptoms may include fever, rash,... more...

Related Diseases for Toxic Shock Syndrome

Diseases related to Toxic Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1428)
# Related Disease Score Top Affiliating Genes
1 critical covid-19 31.9 TNF IL6 IL2 IL1B IL10 CXCL8
2 melioidosis 31.7 TREM1 TNF TLR4 TLR2 IL6 IL10
3 necrotizing fasciitis 31.4 TNF MYOM2 IL6 IL1B CXCL8 CRP
4 disseminated intravascular coagulation 31.4 TNF IL6 IL10 CRP
5 exanthem 31.3 TNF IL6 IL4 IL2 IL1B IL10
6 adult syndrome 31.2 TNF IL6 CRP
7 fasciitis 31.2 TNF MYOM2 LTA IL6 IL2 IL1RN
8 myositis 31.1 TNF IL6 IL1B IFNG
9 kawasaki disease 31.1 TNF TLR2 CRP
10 hyperglycemia 31.1 TNF TLR2 NOS2 IL6
11 congestive heart failure 31.0 TNF IL6 IL1B EDNRA
12 pharyngitis 31.0 TNF TLR2 MYOM2 IL6 IL1B CXCL8
13 cellulitis 31.0 TNF MYOM2 IL6 IL1B CXCL8 CRP
14 scarlet fever 30.9 TNF MYOM2 IL6 IL1B EDNRA CRP
15 lymphopenia 30.9 IL6 IL4 IL2 IL10 IFNG
16 urinary tract obstruction 30.9 TNF IL6 IL1B CRP
17 infective endocarditis 30.9 IL6 CXCL8 CRP
18 urinary tract infection 30.9 TNF TLR4 TLR2 IL6 IL1B IL10
19 pyomyositis 30.9 MYOM2 CRP
20 diarrhea 30.9 TNF TLR4 IL6 IL2 IL1B IL10
21 critical illness polyneuropathy 30.8 TNF IL6 CRP
22 pulmonary hypertension 30.8 TNF NOS2 IL6 EDNRA CRP
23 miliary tuberculosis 30.8 TNF IL4 IL2 IL10 IFNG CRP
24 impetigo 30.8 MYOM2 IL6 EDNRA
25 severe cutaneous adverse reaction 30.7 TNF IL6 IFNG CRP
26 bursitis 30.7 TNF IL6 IL1B CRP
27 tracheitis 30.7 TNF IL6 IL1B IL10 CXCL8 CRP
28 legionnaire disease 30.7 TNF TLR2 IL6 IL1B CRP
29 acute pyelonephritis 30.7 TNF TLR4 IL6 IL1B CXCL8 CRP
30 chickenpox 30.7 TNF IL6 IL4 IL2 IL1B IL10
31 strongyloidiasis 30.7 IL4 IL10 IFNG
32 vaginal discharge 30.7 TNF IL6 IL1B IL10 CXCL8 CRP
33 chikungunya 30.7 TNF IL6 IL1B CRP
34 intestinal perforation 30.7 TNF IL6 IL10 CRP
35 alcoholic liver cirrhosis 30.7 TNF IL6 IL1B CXCL8
36 peripheral vascular disease 30.7 TNF IL6 IL1B CRP
37 hypereosinophilic syndrome 30.6 IL4 IL2 IL10 IFNG CXCL8
38 endometritis 30.6 TNF TLR4 TLR2 IL6 IL1B CXCL8
39 aspiration pneumonia 30.6 TNF IL6 IL1B CXCL8 CRP
40 pericardial effusion 30.6 TNF IL6 CRP
41 reactive arthritis 30.6 TNF LBP CRP
42 acute kidney tubular necrosis 30.6 TNF IL6 IL1B CRP
43 human cytomegalovirus infection 30.6 TNF IL6 IL10
44 mastitis 30.6 TREM1 TLR2 LBP IL6 IL1RN EDNRA
45 measles 30.6 TLR4 TLR2 IL6 IL2 IL1B
46 systemic onset juvenile idiopathic arthritis 30.6 MIF IL6
47 shigellosis 30.6 LTA IL1B IL10
48 actinomycosis 30.6 TNF IL10 CRP
49 post-traumatic stress disorder 30.6 IL6 IL1B CRP
50 histiocytosis 30.6 TNF IL4 IFNG

Graphical network of the top 20 diseases related to Toxic Shock Syndrome:



Diseases related to Toxic Shock Syndrome

Symptoms & Phenotypes for Toxic Shock Syndrome

Symptoms:

11
  • hypotension
  • vomiting
  • fever
  • headache
  • diarrhea
  • rash
  • multiorgan failure
  • desquamation
  • nonfocal neurologic abnormalities

UMLS symptoms related to Toxic Shock Syndrome:


shock without mention of trauma

GenomeRNAi Phenotypes related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 CIITA CRP CXCL8 EDNRA IFNG IL1B
2 no effect GR00402-S-2 10.15 CIITA CRP IFNG IL10 IL1B IL1RN
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.8 CXCL8 IL10 IL1B LTA NOS2 TNF
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.8 CXCL8 IL10 IL1B IL2 LTA NOS2
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.8 NOS2

MGI Mouse Phenotypes related to Toxic Shock Syndrome:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.46 CIITA CRP EDNRA IFNG IL10 IL1B
2 growth/size/body region MP:0005378 10.34 EDNRA IFNG IL10 IL1B IL1RN IL2
3 nervous system MP:0003631 10.33 EDNRA IFNG IL10 IL1B IL4 IL6
4 immune system MP:0005387 10.32 CIITA CRP EDNRA IFNG IL10 IL1B
5 neoplasm MP:0002006 10.3 IFNG IL10 IL1B IL2 IL6 MIF
6 liver/biliary system MP:0005370 10.26 IFNG IL10 IL2 IL4 IL6 LBP
7 cardiovascular system MP:0005385 10.25 CRP EDNRA IFNG IL10 IL1B IL1RN
8 endocrine/exocrine gland MP:0005379 10.22 CIITA EDNRA IFNG IL10 IL2 IL4
9 cellular MP:0005384 10.21 EDNRA IFNG IL10 IL1RN IL2 IL4
10 digestive/alimentary MP:0005381 10.16 EDNRA IFNG IL10 IL2 IL4 IL6
11 muscle MP:0005369 10.14 EDNRA IFNG IL10 IL6 NOS2 TLR2
12 skeleton MP:0005390 10.07 CIITA EDNRA IFNG IL10 IL1B IL1RN
13 respiratory system MP:0005388 10.06 EDNRA IFNG IL10 IL2 IL4 IL6
14 vision/eye MP:0005391 9.9 EDNRA IFNG IL10 IL2 IL4 IL6
15 hematopoietic system MP:0005397 9.89 CIITA EDNRA IFNG IL10 IL1B IL1RN
16 integument MP:0010771 9.4 EDNRA IFNG IL10 IL1B IL1RN IL4

Drugs & Therapeutics for Toxic Shock Syndrome

Drugs for Toxic Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylene blue Approved, Investigational Phase 4 61-73-4 6099
2
Dobutamine Approved Phase 4 34368-04-2 36811
3
Propafenone Approved Phase 4 34183-22-7, 54063-53-5 4932
4
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Succinylcholine Approved Phase 4 306-40-1, 71-27-2 5314
7
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 2826718
8
Micafungin Approved, Investigational Phase 4 235114-32-6 477468
9
Protein C Approved Phase 4
10
Carbamide peroxide Approved Phase 4 124-43-6
11
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
12
Ceftriaxone Approved Phase 4 73384-59-5 5479530
13
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
14
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
15
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
16
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
17
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
18
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
19
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
20
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
21
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
22
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
25
Tazobactam Approved Phase 4 89786-04-9 123630
26
Piperacillin Approved Phase 4 66258-76-2 43672
27
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
28
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
29
Racephedrine Approved, Experimental Phase 4 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
30
Phenylephrine Approved Phase 4 59-42-7 6041
31
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
32
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
33
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
34
Choline Approved, Nutraceutical Phase 4 62-49-7 305
35
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
36
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
37
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
38 Fibrinolytic Agents Phase 4
39 Antimetabolites Phase 4
40 Hypolipidemic Agents Phase 4
41 Lipid Regulating Agents Phase 4
42 Liver Extracts Phase 4
43 Antirheumatic Agents Phase 4
44 Anti-Inflammatory Agents, Non-Steroidal Phase 4
45 Excitatory Amino Acid Antagonists Phase 4
46 Anesthetics, Dissociative Phase 4
47 Analgesics, Opioid Phase 4
48 Narcotics Phase 4
49 Urinastatin Phase 4
50 Trypsin Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 812)
# Name Status NCT ID Phase Drugs
1 Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the TerliNor Study Unknown status NCT03336814 Phase 4 Terlipressin
2 Potential Differences Between Levosimendan and Milrinone on Myocardial and Hemodynamic Variables in Patients With Septic Cardiomyopathy. Effects of Norepinephrine on Right Ventricular Function in Patient With Septic Shock. Unknown status NCT02640846 Phase 4 Norepinephrine;Milrinone;Levosimendan
3 The Effect of Early Goal Directed Sedation on Microcirculation in Septic Shock Patients With Mechanical Ventilation Unknown status NCT02612363 Phase 4 Dexmedetomidine for sedation
4 The Effect of Dexmedetomidine on Microcirculation in Septic Shock- A Double-blinded Study Unknown status NCT02612181 Phase 4 Dexmedetomidine for dexmedetomidine group
5 Effects of Low-chlorine Vs High-chlorine Crystalloid Solutions in Septic Shock Adults Unknown status NCT04365010 Phase 4 Sodium Bicarbonate Ringer's Injection;0.9% Sodium Chloride Injection
6 Simvastatin in Patients With Septic Shock Unknown status NCT00450840 Phase 4 Simvastatin
7 A Randomized Controlled Multi-Center Trial of the Early Application of CRRT in Patients With Severe Sepsis or Septic Shock Unknown status NCT00837057 Phase 4
8 Effects of Vitamin C, Thiamine and Hydrocortisone in Septic Shock: a Randomized, Controlled Trial Unknown status NCT04039815 Phase 4 Ascorbic acid-Vitamin B1-Hydrocortisone;Placebo
9 Hupophosphatemia Levels Deleteriously Affect Outcome of Patients With Severe Sepsis/Septic Shock Admitted to ICU Unknown status NCT04519762 Phase 4 Glycophos (Sodium Glycerophosphate);Antibiotics;Inotropes
10 Pharmacokinetics Variability of Ceftriaxone in Septic ICU Patients Unknown status NCT00449800 Phase 4 ceftriaxone
11 The Effect of Restrictive Fluid Management on Cardiac Function and Glycocalyx Degradation, a Preplanned Substudy of the CLASSIC Trial Unknown status NCT04282252 Phase 4 I.V. SOLUTIONS
12 Double Blinded, Randomized Trial, Comparing Intravenous Bolus of 50 mg of Hydrocortisone Every 6 Hours for 7 Days With a Continuous Infusion of 300 mg Per Day of Hydrocortisone 300-mg Group During 5 Days in the Treatment of Septic Shock. Completed NCT02768740 Phase 4 Hydrocortisone hemisuccinate
13 Continuous Administration of Norepinephrine Assisted by Fuzzy Logic Assisted Control in Septic Shock Patients Completed NCT00763906 Phase 4
14 The Effect of Fluids and Norepinephrine for Mean Arterial Pressure Titration to Patients' Usual Levels on the Microcirculation of Initial Resuscitated Hypertensive Septic Shock Patients. Completed NCT02085291 Phase 4 Norepinephrine;Crystalloid
15 Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients Completed NCT03911817 Phase 4 Midodrine
16 Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial Completed NCT02266264 Phase 4 Hydrocortisone
17 Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (CLASSIC) - a Randomised Clinical Trial Completed NCT02079402 Phase 4 Isotonic crystalloids
18 Prospective Randomized Study of Efficacy and Safety of 1c Class Antiarrhythmic Agent (Propafenone) in Septic Shock Completed NCT03029169 Phase 4 Propafenone i.v.;Amiodarone i.v.
19 Dexmedetomidine Improve Microcirculatory Alterations in Initial Resuscitated Septic Shock Patients Completed NCT02270281 Phase 4 Dexmedetomidine 0.7 Mcg/kg/h
20 A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China Completed NCT02647554 Phase 4 ulinastatin;Placebo
21 Adrenal Cortical Function and Vitamin A Deficiency in Sepsis, Severe Sepsis and Septic Shock: Prospective Randomized, Double Blind Placebo Controlled Clinical Trials Completed NCT03152474 Phase 4 Solumedrol 20mg;Vitamin A 100,000 IU
22 Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis Completed NCT02805049 Phase 4 Echinocandins
23 Ketamine-based Versus Opioid-based for Rapid-sequence Induction of Anesthesia in Patients With Septic Shock Completed NCT03251170 Phase 4 Ketamine;Fentanyl;Midazolam
24 An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock Completed NCT00279214 Phase 4 drotrecogin alfa (activated)
25 Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension Completed NCT02519699 Phase 4 norepinephrine
26 Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Amikacin in Patients With Severe Sepsis or Septic Shock Admitted at the Emergency Department(ED) Completed NCT02365272 Phase 4 Amikacin
27 Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults Completed NCT04492280 Phase 4 Hydrocortisone
28 A Randomised Blinded Placebo Controlled Trial of Hydrocortisone in Critically Ill Patients With Septic Shock Completed NCT01448109 Phase 4 Hydrocortisone;Sterile air filled vial
29 Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units Completed NCT02213796 Phase 4 Meropenem
30 Hemodynamic Assessment With Transpulmonary Thermodilution and Transesophageal Echocardiography in Patients With Early Septic Shock Completed NCT01188993 Phase 4
31 Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C Completed NCT02885168 Phase 4 Recombinant Activated Protein C;Phenylephrine
32 Does Targeted Abdominal Perfusion Pressure Reduce Renal Injury and Mortality in Septic Shock Patients? A Prospective Controlled Trial Completed NCT05358912 Phase 4 Vasopressor Agent;Crystalloid Solutions
33 Population Pharmacokinetics and Pharmacodynamics Study of Piperacillin/Tazobactam During Early Phase in Critically Ill Patients With Severe Sepsis Completed NCT02730624 Phase 4 Piperacillin-tazobactam
34 Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue in Sepsis: A Randomized Controlled Trial Completed NCT03120637 Phase 4 Methylene Blue
35 Dispositivo Adsorbente Con Polymyxina B Immobilizzata Nello Shock Settico - Studio Clinico Randomizzato e Prospettico, Multicentrico Completed NCT00629382 Phase 4
36 Investigating Nutritional Therapy With EPA, GLA and Antioxidants Role in Sepsis Treatment-INTERSEPT STUDY Completed NCT00329680 Phase 4
37 Multicenter, Prospective, Randomized, Controlled Open Study Albumin 20% Versus Saline Completed NCT00327704 Phase 4 albumin;saline
38 Basel Study for Evaluation of Starch (130;0.4) Infusion in Septic Patients: BaSES (130;0.4) Trial Completed NCT00273728 Phase 4 hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline
39 Influence of Sepsis, Age and SLCO1A2 Genetic Polymorphisms on Rocuronium Pharmacokinetics-pharmacodynamics in ASA I-III Surgical Patients Completed NCT02399397 Phase 4 General anesthesia
40 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
41 Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis Completed NCT01310790 Phase 4
42 Renin and Renal Biomarker Response to Angiotensin II Versus Controls in Septic Shock: An Open-Label Study Recruiting NCT04558359 Phase 4 Angiotensin II
43 Comparison of Extubation Delay After Prolonged Sedation With Inhaled Isoflurane Using the MIRUS® Device or Continuous Intravenous Midazolam in Patients With Septic Shock in Intensive Care Recruiting NCT04710914 Phase 4 Prolonged sedation with isoflurane;Prolonged sedation with midazolam
44 Albumin and Crystalloid Administration in Septic Shock (ALCAMIST): Multi-center, Open Labelled Randomized Controlled Trial Recruiting NCT05148286 Phase 4 Treatment;Placebo
45 Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP) Recruiting NCT03068741 Phase 4 Comparison 1: Prehospital Ceftriaxone;Comparison 1: Placebo;Comparison 2: Liberal fluids;Comparison 2: Conservative fluids
46 To Compare 20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid and Identify Fluid Responsiveness Criteria in Critically Ill Patients With Cirrhosis With Sepsis Induced Hypotension; a Prospective Randomized Controlled Trial. Recruiting NCT05441878 Phase 4 20% albumin;Balanced salt solution
47 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial Active, not recruiting NCT03668236 Phase 4 Isotonic crystalloids
48 A Randomized Controlled Pilot Trial of Angiotensin II Versus Vasopressin as Second-line Vasopressor in the Treatment of Septic Shock Not yet recruiting NCT05193370 Phase 4 Angiotensin II;Vasopressin
49 The Impact of Optimized Caloric-proteic Nutrition on Clinical Outcome and Physical Component Summary (PCS) of Quality of Life in Septic and Septic Shock Patients Terminated NCT02731144 Phase 4
50 An Open-label, Prospective, Randomized, Controlled Clinical Trial of the Use of Reduced Duration Versus Standard Duration Steroid Replacement Therapy for Acute Adrenal Insufficiency in Patients With Septic Shock Terminated NCT00842933 Phase 4 Corticosteroid

Search NIH Clinical Center for Toxic Shock Syndrome

Cochrane evidence based reviews: shock, septic

Genetic Tests for Toxic Shock Syndrome

Anatomical Context for Toxic Shock Syndrome

Organs/tissues related to Toxic Shock Syndrome:

MalaCards : Kidney, Skin, Skeletal Muscle, Neutrophil, Liver, Endothelial, Heart

Publications for Toxic Shock Syndrome

Articles related to Toxic Shock Syndrome:

(show top 50) (show all 30601)
# Title Authors PMID Year
1
Why not treat human cancer with interleukin-1 blockade? 53 62
20422276 2010
2
Spectrum of sepsis, mediators, source control and management of bundles. 53 62
20515762 2010
3
Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. 53 62
20421309 2010
4
Sepsis, leukocytes, and nitric oxide (NO): an intricate affair. 53 62
19789465 2010
5
Activated protein C and hospital mortality in septic shock: a propensity-matched analysis. 53 62
20154607 2010
6
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. 53 62
20004006 2010
7
The septic shock-associated IL-10 -1082 A > G polymorphism mediates allele-specific transcription via poly(ADP-Ribose) polymerase 1 in macrophages engulfing apoptotic cells. 53 62
20181890 2010
8
Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. 53 62
20119647 2010
9
C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. 53 62
19717486 2010
10
Augmentation of platelet and endothelial cell eNOS activity decreases sepsis-related neutrophil-endothelial cell interactions. 53 62
19536045 2010
11
The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients. 53 62
20051843 2010
12
The importance of determining procalcitonin and C reactive protein in different stages of sepsis. 53 62
20192933 2010
13
[Gene polymorphisms of Toll-like receptors in Chinese Han children with sepsis in Wenzhou]. 53 62
20441696 2010
14
A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. 53 62
20165718 2010
15
Toll-like receptor 4 modulation as a strategy to treat sepsis. 53 62
20396414 2010
16
beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. 53 62
19850944 2010
17
Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock. 53 62
20181046 2010
18
Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. 53 62
20472994 2010
19
Immunogenicity of toxins during Staphylococcus aureus infection. 53 62
19947854 2010
20
Sick adrenal or sick euadrenal? 53 62
20001882 2009
21
Serum macrophage migration inhibitory factor reflects adrenal function in the hypothalamo-pituitary-adrenal axis of septic patients: an observational study. 53 62
20021698 2009
22
Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. 53 62
19450686 2009
23
Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. 53 62
19760208 2009
24
Relation of heart rate variability to serum levels of C-reactive protein, interleukin 6, and 10 in patients with sepsis and septic shock. 53 62
19327330 2009
25
Angiopoietin balance in septic shock patients treated by direct hemoperfusion with polymyxin b-immobilized fiber. 53 62
19954476 2009
26
Evidence lost to treatment of critically-ill patients? 53 62
19940825 2009
27
Early suspension of activated protein C treatment in septic patients after shock reversal. 53 62
19474736 2009
28
C-reactive protein is not a useful indicator for infection in surgical intensive care units. 53 62
20512289 2009
29
Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. 53 62
20146868 2009
30
The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. 53 62
19652948 2009
31
Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. 53 62
19793001 2009
32
Urgent care in gynaecology: resuscitation and management of sepsis and acute blood loss. 53 62
19596611 2009
33
Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. 53 62
19740375 2009
34
Hemodynamic resuscitation in septic shock: cardiovascular support and adjunctive therapy. 53 62
19698279 2009
35
Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. 53 62
19551369 2009
36
Soluble TNFR II/IgG1 Fc fusion protein treatment in the LPS-mediated septic shock of rats. 53 62
18848768 2009
37
[Study the effects of high-volume hemofiltration and fluid resuscitation on removing blood lactic acid and pro-inflammatory cytokines in patients with refractory septic shock]. 53 62
19615135 2009
38
Combined use of extracorporeal membrane oxygenation and activated protein C for severe acute respiratory distress syndrome and septic shock. 53 62
19577093 2009
39
Influence of antithrombin and argatroban on disseminated intravascular coagulation parameters in a patient with septic shock. 53 62
19062078 2009
40
Release of melanotroph- and corticotroph-type proopiomelanocortin derivatives into blood after administration of corticotropin-releasing hormone in patients with septic shock without adrenocortical insufficiency. 53 62
18827746 2009
41
Angiopoietin-2 is increased in septic shock: evidence for the existence of a circulating factor stimulating its release from human monocytes. 53 62
19539650 2009
42
[Prognostic values of B-type natriuretic peptide in severe sepsis and septic shock]. 53 62
19439118 2009
43
Mechanisms of human complement factor B induction in sepsis and inhibition by activated protein C. 53 62
19279234 2009
44
Antithrombosis Trials: Should we test therapeutic heparin adjusted based on activated partial thromboplastin time in septic shock? 53 62
19318828 2009
45
Prevalence of occult adrenal insufficiency and the prognostic value of a short corticotropin stimulation test in patients with septic shock. 53 62
19881189 2009
46
Serum of patients with septic shock stimulates the expression of Trem-1 on U937 monocytes. 53 62
19109693 2009
47
Vasopressin and its copilot copeptin in sepsis and septic shock. 53 62
19325368 2009
48
The vasopressin and copeptin response to infection, severe sepsis, and septic shock. 53 62
19114902 2009
49
Effects of liposome-encapsulated hemoglobin on human immune system: evaluation in immunodeficient mice reconstituted with human cord blood stem cells. 53 62
19178463 2009
50
Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. 53 62
19181857 2009

Variations for Toxic Shock Syndrome

Expression for Toxic Shock Syndrome

Search GEO for disease gene expression data for Toxic Shock Syndrome.

Pathways for Toxic Shock Syndrome

Pathways related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 CIITA CRP CXCL8 IFNG IL10 IL1B
2
Show member pathways
13.89 TNF NOS2 LTA IL6 IL4 IL2
3
Show member pathways
13.73 TNF TLR4 NOS2 MIF LTA IL6
4
Show member pathways
13.64 TNF LTA IL6 IL4 IL2 IL1B
5
Show member pathways
13.61 TREM1 TNF TLR4 TLR2 LBP IL6
6
Show member pathways
13.55 TNF TLR4 TLR2 LTA IL6 IL4
7
Show member pathways
13.41 CXCL8 IL10 IL1B IL2 IL4 IL6
8
Show member pathways
13.38 CIITA CXCL8 IFNG IL10 IL1B IL1RN
9
Show member pathways
13.04 TLR4 TLR2 NOS2 IL6 IL4 IL2
10
Show member pathways
13 TREM1 TNF TLR4 TLR2 LBP IL6
11
Show member pathways
12.91 TNF LTA IL6 IL4 IL2
12
Show member pathways
12.87 TNF TLR4 TLR2 LTA IL6 IL2
13
Show member pathways
12.8 TNF TLR2 NOS2 IL6 IL1RN IL1B
14
Show member pathways
12.8 TNF LTA IL6 IL4 IL2 IL1B
15
Show member pathways
12.77 TNF NOS2 IL6 IL2 IL1B IL10
16 12.72 CIITA IFNG IL10 IL1B IL1RN IL2
17
Show member pathways
12.7 IL1B LTA TLR2 TLR4 TNF
18
Show member pathways
12.69 CXCL8 IL1B IL6 TLR2 TLR4 TNF
19
Show member pathways
12.46 TNF TLR4 NOS2 MIF LBP IL6
20
Show member pathways
12.46 CXCL8 IFNG IL1B IL1RN IL4 IL6
21 12.37 TNF TLR4 TLR2 NOS2 IL6 IFNG
22
Show member pathways
12.35 TNF TLR2 IL6 CXCL8
23 12.35 TNF IL6 IL1RN IL1B IL10 CXCL8
24
Show member pathways
12.32 TNF LTA IL4 IL2 IL10 IFNG
25
Show member pathways
12.28 TNF IL4 IL2 IFNG
26 12.28 TNF LTA IL6 IL4 IL1B IL10
27 12.19 TNF IL6 IL4 IL2 IL10 IFNG
28
Show member pathways
12.16 NOS2 IL4 IL2 IL1B IFNG
29
Show member pathways
12.13 TLR4 TLR2 IL2 IL1B
30
Show member pathways
12.13 LTA IL4 IL2 IFNG
31 12.11 TNF NOS2 LBP IL6 IL4 IL1B
32 12.07 IL6 IL1B IFNG CXCL8
33
Show member pathways
12.06 TLR4 TLR2 IL6 IL4 IL1B IFNG
34 12.05 TNF IL4 IL2 IL1B IL10 IFNG
35 12.02 CXCL8 IFNG IL1B IL2 IL4 IL6
36
Show member pathways
12.01 TLR4 LBP IL6 CXCL8
37 11.98 IL6 IL4 IL2 IFNG CXCL8
38 11.97 TNF LTA IL4 IL2 IL1B IL10
39 11.96 IFNG IL10 IL2 IL6 TLR4
40 11.96 CXCL8 IL1B IL6 TLR4 TNF
41 11.96 TNF IL6 IL2 IL1B IL10 IFNG
42
Show member pathways
11.94 TNF LTA IL1B IFNG
43
Show member pathways
11.92 LBP IL6 CXCL8 CRP
44 11.91 IL6 IL4 IL2 IL1B IFNG
45 11.91 IL6 IL4 IL2 IL10 IFNG CXCL8
46
Show member pathways
11.9 TNF IL4 IL2 IFNG CXCL8
47 11.89 CRP IFNG IL10 IL2 IL4 IL6
48
Show member pathways
11.86 LTA IL2 CXCL8
49 11.86 TNF IL6 IL4 IL1B CXCL8
50 11.85 TNF TLR4 IL6 IL10 CXCL8

GO Terms for Toxic Shock Syndrome

Cellular components related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.07 TREM1 TNF MIF LTA LBP IL6
2 extracellular space GO:0005615 9.74 CRP CXCL8 IFNG IL10 IL1B IL1RN

Biological processes related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.68 TNF TLR4 TLR2 IL6 IL4 IL2
2 signal transduction GO:0007165 10.59 CXCL8 EDNRA IFNG IL10 IL1B IL1RN
3 positive regulation of gene expression GO:0010628 10.49 CRP CXCL8 IFNG IL1B IL4 IL6
4 negative regulation of cell population proliferation GO:0008285 10.48 TNF TLR2 IL6 IL1B IL10 CXCL8
5 response to hypoxia GO:0001666 10.39 TNF TLR2 NOS2 LTA EDNRA
6 positive regulation of DNA-binding transcription factor activity GO:0051091 10.34 TNF IL6 IL1B IL10
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.34 TNF TLR4 TLR2 IL6 IL1B
8 defense response to bacterium GO:0042742 10.33 TNF TLR4 NOS2 LBP IL10
9 defense response to Gram-negative bacterium GO:0050829 10.32 TLR4 NOS2 LBP IL6
10 neutrophil chemotaxis GO:0030593 10.31 CXCL8 IL1B LBP TREM1
11 cellular response to lipopolysaccharide GO:0071222 10.31 CXCL8 IL10 IL1B IL6 LBP NOS2
12 positive regulation of MAP kinase activity GO:0043406 10.3 TNF TLR4 MIF IL1B
13 negative regulation of tumor necrosis factor production GO:0032720 10.3 IL10 IL4 LBP TLR4
14 positive regulation of type II interferon production GO:0032729 10.3 TNF TLR4 LTA IL2 IL1B
15 positive regulation of inflammatory response GO:0050729 10.3 TNF TLR4 TLR2 IL2 IL1B IFNG
16 defense response to Gram-positive bacterium GO:0050830 10.3 TNF TLR2 LTA LBP IL6 IL1B
17 inflammatory response GO:0006954 10.3 TNF TLR4 TLR2 NOS2 MIF IL6
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.29 IL1B TLR2 TLR4 TNF
19 positive regulation of interleukin-1 beta production GO:0032731 10.28 IFNG IL6 TLR4 TNF
20 response to glucocorticoid GO:0051384 10.27 TNF IL6 IL1RN IL10
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.27 IFNG IL2 IL4 IL6 TNF
22 humoral immune response GO:0006959 10.27 TREM1 TNF LTA IL6 IFNG
23 positive regulation of tumor necrosis factor production GO:0032760 10.27 IFNG IL6 LBP MIF TLR2 TLR4
24 positive regulation of B cell proliferation GO:0030890 10.26 TLR4 MIF IL4 IL2
25 cellular response to type II interferon GO:0071346 10.26 CIITA NOS2 TLR2 TLR4 TNF
26 positive regulation of cytokine production GO:0001819 10.24 TNF MIF IL1B IL10 IFNG
27 positive regulation of interleukin-12 production GO:0032735 10.23 IFNG TLR2 TLR4
28 positive regulation of nitric oxide biosynthetic process GO:0045429 10.23 IFNG IL1B TLR4 TNF
29 positive regulation of interleukin-10 production GO:0032733 10.23 TLR4 TLR2 IL6 IL4
30 immune system process GO:0002376 10.22 TREM1 TLR4 TLR2 MIF LBP IL2
31 acute-phase response GO:0006953 10.22 CRP IL6 LBP
32 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.22 TNF IL6 IL10
33 positive regulation of T cell proliferation GO:0042102 10.22 IL6 IL4 IL2 IL1B
34 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.22 EDNRA IL1B TLR4 TNF
35 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 10.21 IL4 IL2 IL1B
36 regulation of insulin secretion GO:0050796 10.21 TNF NOS2 IL6 IL1B IFNG
37 liver regeneration GO:0097421 10.2 TNF IL6 IL10
38 positive regulation of immunoglobulin production GO:0002639 10.2 IL6 IL2 IL10
39 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.2 TNF TLR4 IL6
40 negative regulation of neurogenesis GO:0050768 10.19 TNF IL6 IL1B
41 microglial cell activation GO:0001774 10.19 IFNG IL4 TLR2 TNF
42 positive regulation of macrophage activation GO:0043032 10.18 TLR4 LBP IL10
43 lipopolysaccharide-mediated signaling pathway GO:0031663 10.18 TNF TLR4 TLR2 LBP IL1B
44 response to lipopolysaccharide GO:0032496 10.18 TNF TLR4 TLR2 NOS2 LTA LBP
45 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 10.17 TLR4 TLR2 IFNG
46 positive regulation of interleukin-8 production GO:0032757 10.17 IL1B IL6 LBP NOS2 TLR2 TLR4
47 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10.16 TNF IL1B IFNG
48 positive regulation of glial cell proliferation GO:0060252 10.16 TNF LTA IL6 IL1B
49 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.14 TNF IL1B IL10
50 astrocyte activation GO:0048143 10.14 IFNG IL1B TNF

Molecular functions related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.64 TNF MIF LTA IL6 IL4 IL2
2 lipopolysaccharide immune receptor activity GO:0001875 9.46 TLR4 TLR2
3 lipopolysaccharide binding GO:0001530 9.43 TLR4 TLR2 LBP

Sources for Toxic Shock Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....